Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Genetic Test Improves Risk Prediction for Open-Angle Glaucoma

By LabMedica International staff writers
Posted on 19 Nov 2026

Glaucoma damages the optic nerve and is the leading cause of irreversible blindness worldwide. More...

Because the disease often causes no early symptoms, about half of affected individuals remain undiagnosed even in countries with good access to eye care. Since vision loss cannot be reversed once it occurs, identifying people at higher risk before significant damage develops remains a major diagnostic challenge.

Researchers at QIMR Berghofer Medical Research Institute and Flinders University, working with international collaborators, developed the new genetic test to assess risk for open-angle glaucoma, the most common form of the disease. Findings published in Ophthalmology show that the test improves on an earlier version and may help identify people at elevated risk before significant vision loss occurs.

The test uses a polygenic risk score that combines the effects of millions of genetic variations into a single measure of inherited risk. Researchers developed the score using genetic data from more than six million people, including nearly 300,000 individuals with glaucoma. By comparison, the previous version, published in 2020, was based on approximately 8,000 glaucoma cases.

Among Australians of European ancestry, people in the highest 10% of genetic risk were 10 times more likely to have glaucoma than those outside this group. They also developed glaucoma approximately 25 years earlier, on average, than individuals in the lowest 10% of genetic risk. In a long-term study of people with suspected or early glaucoma, 24% of those in the highest-risk group required glaucoma surgery by age 80, compared with none in the lowest-risk group.

The score also helped predict disease severity, the need for more intensive treatment, and the likelihood of glaucoma among family members. It provided additional predictive information beyond eye pressure measurements, which the researchers identify as the most commonly assessed glaucoma risk factor. 

The score was evaluated in people of European, African, East Asian, South Asian, and Hispanic ancestry, with the strongest performance observed in those of European ancestry. Further research is needed to assess the cost-effectiveness of incorporating the test into targeted glaucoma screening programs.

“In Australians of European ancestry, people in the highest 10% of genetic risk were 10 times more likely to have glaucoma than everyone else. Our earlier test identified about a fourfold increase in risk. To our knowledge, this is the strongest genetic risk prediction reported for any common complex disease,” said Stuart MacGregor, lead researcher and head of QIMR Berghofer's Statistical Genetics Laboratory. 

“Most of the large genetic data sets available today come from people of European ancestry. Improving accuracy for all populations is an important priority for our next phase of work,” added MacGregor.

Related Links
QIMR Berghofer Medical Research Institute
Flinders University


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Slide Scanner System
NanoZoomer S540MD
Gold Member
Serum Indices Control
Acusera Serum Indices Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Led by Professor Sherry Chan Kit-wa (middle), the HKUMed research team provides the first large-scale Chinese population evidence to support reviewing Hong Kong’s long-term blood-monitoring requirements for clozapine use. (Photo courtesy of HKUMed)

Study Supports Review of Long-Term Blood-Monitoring Guidelines for Clozapine

Treatment-resistant schizophrenia (TRS) is a severe form of schizophrenia for which clozapine remains the only antipsychotic specifically approved by the U.S. Food and Drug Administration (FDA).... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image

Labcorp Partners With Grupo Fleury to Expand Clinical Trial Operations in Brazil

Multinational clinical trials require laboratory partners that combine global expertise with local operational capabilities. Brazil is an important clinical research destination, supported by its diverse... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.